Corporate Report

The report covers April 2019-March 2020 and highlights consolidated net sales of ¥89,232 million alongside 1,268 consolidated employees. It describes five priority issues spanning medical responsibility, governance, the environment and fulfilling workplaces, selected through business-relevance and stakeholder-impact mapping. Environmental disclosures include FY2019 CO2 emissions of 21,279 t-CO2 and waste produced of 618 tons at the Shizuoka site and Kyoto Drug Research Center. The company also reports appointing a female outside director and continuing employee health, safety and training initiatives.